Real-world Data in Patients With Breast Cancer Treated With Abemaciclib
ConditionBreast Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHellenic Cooperative Oncology Group
About this trial
The present study will assess real-world clinical outcomes and adverse events from treatment with endocrine therapy combined with abemaciclib in patients with HR-positive, HER2-negative advanced breast cancer.
Eligibility criteria
Qualifiers
Histologically confirmed HR-positive, HER2-negative breast cancer
Treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology
18 years or older
Any menopausal status
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
108 Participants
are grouped into 2 trial groupsSponsors and collaborators
Source ClinicalTrials.gov